Roivant Sciences Ltd (FRA:87S)
€ 10.975 -1.02 (-8.5%) Market Cap: 8.42 Bil Enterprise Value: 3.37 Bil PE Ratio: 2.16 PB Ratio: 1.74 GF Score: 60/100

Roivant Sciences Ltd to Provide Update Regarding Initiation of Patent Litigation Against Moderna - Conference Call Transcript

Feb 28, 2022 / 01:00PM GMT
Release Date Price: €5.6 (-1.75%)
Operator

Good day, and thank you for standing by. Welcome to Roivant's update regarding Initiation of Patent Litigation Against Moderna Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Paul Davis. Please go ahead.

Paul Davis
Roivant Sciences, Inc. - Head of Communications

Great. Good morning, and thank you for joining today's call to discuss the initiation of patent litigation against Moderna by Genevant and its licensor Arbutus. I'm Paul Davis, the Head of Communications at Roivant. On the call today, we have Roivant's CEO, Matt Gline; and Dr. Pete Lutwyche, CEO of Genevant.

For those dialing in via conference call, you can find the slides being presented today on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along. We will end the call with a Q&A session.

I'd like to remind

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot